India’s first COVID-19 vaccine candidate COVAXIN has received the approval of drug regulator
DCGI for phase I and II of human clinical trials. The drug has been developed by Bharat Biotech.
Human clinical trials are scheduled to start across India in July 2020.
It has been developed in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech.
The indigenous, inactivated vaccine has been developed and manufactured by Bharat Biotech.